Nasdaq · CIK 0001810560
REVB REVELATION BIOSCIENCES, INC.
Insider trading from SEC Form 4. Last filing Aug 18, 2026.
In brief
REVELATION BIOSCIENCES, INC. (REVB) has 27 SEC Form 4 filings on file from 6 insiders, the latest filed on Aug 18, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at REVB. The newest: George F Tidmarsh (director) sold $14k of stock on Dec 8, 2023, filed Dec 12, 2023, scored 35 (weak).
Last 90 days
Signals
Open-market buys and sells at REVELATION BIOSCIENCES, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | George F Tidmarsh director sell | $14k 27,771 shares | -100% | - | |
| 15Weak | George F Tidmarsh director sell | $1,199 1,845 shares | -6% | - | |
| 20Weak | George F Tidmarsh director sell | $7,243 10,957 shares | -21% | - |
Transactions
Every row filed, 29 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Lakhmir S Chawla director | AGrant or award Common Stock | +32,011 | $0.00 | $0 | 44,169 | Aug 18, 2026 |
| Aug 17, 2026 | Jess Roper director | AGrant or award Common Stock | +32,011 | $0.00 | $0 | 44,839 | Aug 18, 2026 |
| Aug 17, 2026 | Chester Stanley Zygmont III Chief Financial Officer | AGrant or award Common Stock | +208,073 | $0.00 | $0 | 208,073 | Aug 18, 2026 |
| Aug 17, 2026 | James Rolke Chief Executive Officer | AGrant or award Common Stock | +208,076 | $0.00 | $0 | 422,814 | Aug 18, 2026 |
| Aug 17, 2026 | Jennifer Carver director | AGrant or award Common Stock | +32,011 | $0.00 | $0 | 44,769 | Aug 18, 2026 |
| Aug 17, 2026 | Chester Stanley Zygmont III Chief Financial Officer | GGift Common Stock | -208,073 | $0.00 | $0 | 0 | Aug 18, 2026 |
| Aug 17, 2026 | Chester Stanley Zygmont III Chief Financial Officer | GGift Common Stockindirect: by Trust | +208,073 | $0.00 | $0 | 300,136 | Aug 18, 2026 |
| Apr 30, 2026 | Chester Stanley Zygmont III Chief Financial Officer | FTax withholding Common Stockindirect: by Trust | -13,285 | $1.10 | $15k | 92,063 | May 1, 2026 |
| Apr 30, 2026 | James Rolke Chief Executive Officer | FTax withholding Common Stock | -10,115 | $1.13 | $11k | 214,738 | May 1, 2026 |
| Feb 4, 2026 | Chester Stanley Zygmont III Chief Financial Officer | FTax withholding Common Stockindirect: By Trust | -13,100 | $1.65 | $22k | 105,348 | Feb 5, 2026 |
| Feb 3, 2026 | Jennifer Carver director | FTax withholding Common Stock | -1,661 | $1.87 | $3,106 | 12,758 | Feb 5, 2026 |
| Feb 3, 2026 | Lakhmir S Chawla director | FTax withholding Common Stock | -2,261 | $1.85 | $4,183 | 12,158 | Feb 5, 2026 |
| Feb 3, 2026 | James Rolke Chief Executive Officer | FTax withholding Common Stock | -8,521 | $1.86 | $16k | 224,853 | Feb 5, 2026 |
| Feb 3, 2026 | Jess Roper director | FTax withholding Common Stock | -1,591 | $1.85 | $2,943 | 12,828 | Feb 5, 2026 |
| Jan 8, 2026 | Jennifer Carver director | AGrant or award Common Stock | +41,981 | $0.90 | $38k | 57,669 | Jan 12, 2026 |
| Jan 8, 2026 | James Rolke Chief Executive Officer | AGrant or award Common Stock | +532,829 | $0.90 | $480k | 933,489 | Jan 12, 2026 |
| Jan 8, 2026 | Jess Roper director | AGrant or award Common Stock | +41,981 | $0.90 | $38k | 57,667 | Jan 12, 2026 |
| Jan 8, 2026 | Lakhmir S Chawla director | AGrant or award Common Stock | +41,981 | $0.90 | $38k | 57,667 | Jan 12, 2026 |
| Jan 8, 2026 | Chester Stanley Zygmont III Chief Financial Officer | AGrant or award Common Stockindirect: By Trust | +78,145 | $0.90 | $70k | 473,790 | Jan 12, 2026 |
| Oct 29, 2025 | Jennifer Carver director | AGrant or award Common Stock | +15,625 | $1.28 | $20k | 15,688 | Oct 31, 2025 |
| Oct 29, 2025 | Lakhmir S Chawla director | AGrant or award Common Stock | +15,625 | $1.28 | $20k | 15,686 | Oct 31, 2025 |
| Oct 29, 2025 | Jess Roper director | AGrant or award Common Stock | +15,625 | $1.28 | $20k | 15,686 | Oct 31, 2025 |
| Oct 29, 2025 | James Rolke Chief Executive Officer | AGrant or award Common Stock | +390,614 | $1.28 | $500k | 400,660 | Oct 31, 2025 |
| Oct 29, 2025 | Chester Stanley Zygmont III Chief Financial Officer | AGrant or award Common Stockindirect: By Trust | +390,614 | $1.28 | $500k | 395,645 | Oct 31, 2025 |
| Feb 11, 2025 | Lakhmir S Chawla director | AGrant or award Common Stock | +181 | $3.87 | $700 | 181 | Feb 13, 2025 |
| Feb 11, 2025 | Jennifer Carver director | AGrant or award Common Stock | +181 | $3.87 | $700 | 187 | Feb 13, 2025 |
| Dec 8, 2023 | George F Tidmarsh director | SOpen-market sale Common Stock | -27,771 | $0.52 | $14k | 0 | Dec 12, 2023 |
| Oct 16, 2023 | George F Tidmarsh director | SOpen-market sale Common Stock | -1,845 | $0.65 | $1,199 | 27,771 | Oct 18, 2023 |
| Oct 16, 2023 | George F Tidmarsh director | SOpen-market sale Common Stockindirect: By Trust | -10,957 | $0.66 | $7,243 | 42,096 | Oct 17, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Jennifer Carverdirector
- Lakhmir S Chawladirector
- Jess Roperdirector
- James RolkeChief Executive Officer
- George F Tidmarshdirector
- Chester Stanley Zygmont IIIChief Financial Officer
Questions about REVB
Answered from the filings on this page, as of the latest one.
Are insiders buying REVB?
No. In the last 90 days no insider at REVELATION BIOSCIENCES, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade REVB on the open market?
George F Tidmarsh (director) sold $14k of REVB on Dec 8, 2023 and filed the Form 4 on Dec 12, 2023. InsiderTell scored 35 (weak).
How many insiders file Form 4 at REVELATION BIOSCIENCES, INC.?
6 people have filed a Form 4 at REVELATION BIOSCIENCES, INC., among them Jennifer Carver (director), Lakhmir S Chawla (director), Jess Roper (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.